Drug Safety
Admilparant slows lung function decline in IPF, progressive PF
Receiving admilparant, an oral lysophosphatidic acid receptor 1 antagonist, for 26 weeks lowered percent-predicted FVC decline in idiopathic and progressive pulmonary fibrosis, according to study results.
Phase 1 trial of potential treatment for IPF moves forward ‘without any safety concerns’
No safety concerns emerged in part one of the phase 1 trial assessing CS014, a histone deacetylase inhibitor that has potential in treating idiopathic pulmonary fibrosis, in healthy individuals, according to a press release.
FDA grants brensocatib priority review for bronchiectasis
The FDA has granted priority review to brensocatib to treat patients with non-cystic fibrosis bronchiectasis, according to a manufacturer-issued press release.
Dupilumab does not desensitize children with peanut allergy
Following receipt of dupilumab for 24 weeks, desensitization to peanut exposure in most children/adolescents with peanut allergy was not achieved, according to results published in Allergy.
Vanzacaftor, tezacaftor, deutivacaftor safe in children with cystic fibrosis
Patients aged 6 to 11 years with cystic fibrosis receiving 24-week once-daily vanzacaftor/tezacaftor/deutivacaftor generally tolerated it well, according to data published in The Lancet Respiratory Medicine.
Vanzacaftor, tezacaftor, deutivacaftor similar to current cystic fibrosis standard of care
Among individuals aged at least 12 years with cystic fibrosis, receipt of vanzacaftor/tezacaftor/deutivacaftor was similar or better than Trikafta depending on the endpoint, according to results published in The Lancet Respiratory Medicine.
FDA clears investigational new drug application for lorundrostat in OSA, hypertension
The FDA approved the phase 2 Explore-OSA trial set to assess the highly selective aldosterone synthase inhibitor, lorundrostat, in adults with obstructive sleep apnea and hypertension, according to a press release.
Deupirfenidone reduces FVC decline, well tolerated in IPF at 26 weeks
Patients with idiopathic pulmonary fibrosis had less FVC decline between baseline and 26 weeks with receipt of three daily doses of 825 mg deupirfenidone, according to phase 2b ELEVATE IPF trial results.
Topline results: AI-established IPF drug well-tolerated, improves FVC
Patients with idiopathic pulmonary fibrosis had improved FVC between baseline and 12 weeks with receipt of ISM001-055, a small molecule targeting Traf2- and Nck-interacting kinase, vs. placebo, according to topline results.
Interim data show Duravyu improves BCVA, central subfield thickness in DME
EyePoint Pharmaceuticals has announced positive 16-week data from the ongoing phase 2 VERONA trial evaluating Duravyu for patients with diabetic macular edema, according to a press release.